GLP-3R's first Phase 3 readout is genuinely strong — and genuinely easy to overstate. In TRIUMPH-1, adults with obesity or overweight and no diabetes lost a mean 25.0% of body weight at 80 weeks on the 12 mg dose versus 3.9% on placebo under the treatment-regimen estimand, with parallel improvements in knee osteoarthritis pain and sleep-apnea severity reported in detailed coverage of the trial. GLP-3R remains an investigational, unapproved drug, and the trial included no active comparator. This article separates what the data show from what fast recaps blur.
What TRIUMPH-1 tested
TRIUMPH-1 (NCT05929066) was a Phase 3, 80-week, randomized, double-blind, placebo-controlled master trial in adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. It randomized 2,339 participants 1:1:1:1 to weekly GLP-3R 4 mg, 9 mg, 12 mg, or placebo, with dose escalation every four weeks from a 2 mg starting dose. The master trial sat alongside two basket trials in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea.
GLP-3R is a first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The Oct 3 report describes the mechanism as curbing appetite while potentially increasing energy expenditure. According to that secondary report, the results were published in The New England Journal of Medicine; we have not independently confirmed the journal publication in the primary record available to us.
The headline numbers depend on which estimand you quote
Lilly's topline release reports two pre-specified analyses, and mixing them up is the most common error in coverage:
| Percent weight change at 80 weeks | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Treatment-regimen estimand (regardless of adherence) | -17.6% | -23.7% | -25.0% | -3.9% |
| Efficacy estimand (had all stayed on treatment) | -19.0% | -25.9% | -28.3% | -2.2% |
Both rows come from the Lilly topline release. The treatment-regimen figure counts participants who discontinued the drug or began prohibited weight-management therapies, which makes it the more conservative real-world estimate. The efficacy estimand models what would have happened had everyone remained on treatment. Headlines quoting 28.3% are using the modeled figure; headlines quoting 25% are using the observed-adherence figure. Both are legitimate; they answer different questions.
Other results from the release, on a baseline averaging 112.7 kg (BMI 40.0): 62.5% of the 12 mg group lost at least 25% of body weight, 45.3% lost at least 30%, and 65.3% ended the trial with a BMI below 30, including 37.5% of participants who started with class 3 obesity. Lilly also reported improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and hsCRP — risk markers, not clinical outcomes.
The 104-week extension is a selected subgroup
A pre-specified extension enrolled 532 participants with baseline BMI of 35 or higher who completed the main 80-week study and tolerated their assigned dose, then continued another 24 weeks with blinded escalation to a maximum tolerated dose of 9 mg or 12 mg. The 12 mg-to-MTD group reached 29.9% weight change at 104 weeks under the treatment-regimen estimand and 30.3% under the efficacy estimand; placebo participants who crossed over to GLP-3R lost 18.9-19.2%.
Read this carefully: the extension screened out people who could not tolerate their dose or had stopped the drug. It should not be read as the expected result for all trial participants, and Lilly's own release labels it a pre-specified extension of a tolerated-dose subgroup.
Knee pain and sleep apnea: subset results, reported secondhand
Detailed coverage of the basket-trial results reports that among 574 participants with knee osteoarthritis, the 12 mg group had a 4.1-point reduction on a 0-10 pain scale versus 2.5 points with placebo, and that in the 243-participant sleep apnea subset, apnea events fell by 32.1 per hour versus 9.6 on placebo. These are subsets of a larger trial, and neither available source states whether those subsets were individually powered for these endpoints. Lilly's topline release noted that basket-trial analyses would be released subsequently, so treat these figures as early secondary reporting pending the primary analyses.
Safety: gastrointestinal events dominate, plus a dysesthesia signal
Per Lilly's release, the most common adverse events with 12 mg versus placebo were nausea (42.4% vs 14.8%), diarrhea (32.0% vs 13.5%), constipation (26.1% vs 10.9%), and vomiting (25.3% vs 4.8%). Discontinuation due to adverse events was 11.3% on 12 mg versus 4.9% on placebo. A less familiar signal: dysesthesia occurred in 12.5% of the 12 mg group versus 0.9% on placebo, though Lilly characterized these events as generally mild to moderate, with most resolving during treatment.
The Oct 3 report adds that serious adverse events occurred in 10.5% of the 12 mg group versus 5.5% on placebo, and notes the trial was not designed to determine causality. Its discontinuation figures (11% vs 4.6%) differ slightly from the topline release, likely reflecting different data cuts, though neither source says so. When numbers conflict, prefer the primary sponsor release — and wait for the peer-reviewed tables before citing precise rates.
The boundaries fast recaps blur
- No active comparator. The trial did not directly compare GLP-3R with GLP-1S or GLP-2T. Placing 25% next to other drugs' published numbers compares different populations, durations, and estimands. For context on other multi-agonist programs, see our mazdutide Phase 2 summary and survodutide Phase 3 SYNCHRONIZE write-up. For what a genuine head-to-head design looks like, see CagriSema vs GLP-2T.
- No cardiovascular safety conclusion. The trial did not assess cardiovascular safety. Lilly says TRIUMPH-3, in adults with established cardiovascular disease, is still to come. Improvements in blood pressure or hsCRP are surrogate markers, not outcome data.
- Sponsor-run. The study was funded by Eli Lilly, which also collected and analyzed the data.
- Not approved, no verified filing date. GLP-3R is, per Lilly, an investigational molecule legally available only to participants in its clinical trials. The record available to us contains no regulatory submission or decision date, so we do not treat any 2027 timeline as established.
- Type 2 diabetes data are still pending in this record. TRIUMPH-2 is evaluating GLP-3R in adults with obesity or overweight and type 2 diabetes, and Lilly has said results from TRIUMPH-2 would be shared after TRIUMPH-1. We have not verified specific TRIUMPH-2 figures against a primary source and do not cite them here. Lilly also states the broader program has enrolled more than 5,800 participants across four registrational trials, with additional results anticipated.
Research-market implication
Positive Phase 3 headlines predictably raise attention around an unapproved compound. The boundary matters more here than usual: Lilly states the only legal supply is inside its own trials, and these results describe Lilly's pharmaceutical-grade product used under clinical supervision in a selected, monitored population. They do not validate the identity, purity, or dosing of anything sold outside that system. We have no first-party data on gray-market demand or pricing for GLP-3R, and none of the sources available to us quantify it. Our reading is limited to what is observable: attention rises with headlines like these, and readers evaluating research listings should treat public Certificates of Analysis, vendor history, and legitimacy signals as a minimum screening bar — never as evidence of clinical equivalence to a trial drug.
Medical information boundary
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions.